Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Toney

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Journal for Immunotherapy of Cancer|April 14, 2022
Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfaYo-Ting Tsai, Julius Strauss, Nicole J Toney, et al.
Research Square|January 13, 2025
B cells enhance IL-1 beta driven invasiveness in triple-negative breast cancerNicole J Toney, Lynn M Opdenaker, Lisa Frerichs, et al.
Journal of Translational Medicine|March 8, 2022
Tumor-B-cell interactions promote isotype switching to an immunosuppressive IgG4 antibody response through upregulation of IL-10 in triple negative breast cancersNicole J Toney, Lynn M Opdenaker, Kader Cicek, et al.
The Journal of Steroid Biochemistry and Molecular Biology|March 1, 1997
4-Methyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-N-aryl-carboxamides: an approach to combined androgen blockade [5alpha-reductase inhibition with androgen receptor binding in vitro]R L Tolman, S P Sahoo, R K Bakshi, et al.
The Journal of Steroid Biochemistry and Molecular Biology|July 1, 1996
MK386: a potent, selective inhibitor of the human type 1 5alpha-reductaseK Ellsworth, B Azzolina, W Baginsky, et al.
Prostate Cancer and Prostatic Diseases|January 26, 2022
A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)Marijo Bilusic, Nicole J Toney, Renee N Donahue, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2025
Increased peripheral T stem cell-like memory features in patients with advanced solid tumors treated with tumor-targeting IL-12 immunocytokine therapyMeghali Goswami, Carolina Celades, Christine M Minnar, et al.
The Oncologist|January 14, 2023
A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid TumorsMargaret E Gatti-Mays, Nicholas P Tschernia, Julius Strauss, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 26, 2012
Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudyK E Schmader, M N Oxman, M J Levin, et al.
Nature Communications|March 28, 2024
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II studyFilipa Lynce, Candace Mainor, Renee N Donahue, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Journal for Immunotherapy of Cancer|April 14, 2022
Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfaYo-Ting Tsai, Julius Strauss, Nicole J Toney, et al.
Research Square|January 13, 2025
B cells enhance IL-1 beta driven invasiveness in triple-negative breast cancerNicole J Toney, Lynn M Opdenaker, Lisa Frerichs, et al.
Journal of Translational Medicine|March 8, 2022
Tumor-B-cell interactions promote isotype switching to an immunosuppressive IgG4 antibody response through upregulation of IL-10 in triple negative breast cancersNicole J Toney, Lynn M Opdenaker, Kader Cicek, et al.
The Journal of Steroid Biochemistry and Molecular Biology|March 1, 1997
4-Methyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-N-aryl-carboxamides: an approach to combined androgen blockade [5alpha-reductase inhibition with androgen receptor binding in vitro]R L Tolman, S P Sahoo, R K Bakshi, et al.
The Journal of Steroid Biochemistry and Molecular Biology|July 1, 1996
MK386: a potent, selective inhibitor of the human type 1 5alpha-reductaseK Ellsworth, B Azzolina, W Baginsky, et al.
Prostate Cancer and Prostatic Diseases|January 26, 2022
A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)Marijo Bilusic, Nicole J Toney, Renee N Donahue, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2025
Increased peripheral T stem cell-like memory features in patients with advanced solid tumors treated with tumor-targeting IL-12 immunocytokine therapyMeghali Goswami, Carolina Celades, Christine M Minnar, et al.
The Oncologist|January 14, 2023
A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid TumorsMargaret E Gatti-Mays, Nicholas P Tschernia, Julius Strauss, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 26, 2012
Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudyK E Schmader, M N Oxman, M J Levin, et al.
Nature Communications|March 28, 2024
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II studyFilipa Lynce, Candace Mainor, Renee N Donahue, et al.
Pageof 4